



SUVEN Life Sciences Ltd

Communication to investors **December 2018**

5-Feb-19

2018-19 Q3 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

		FY 2018-19 Q3 to Q2	FY 2018-19 YoY 9 months
Growth in revenue		40.24%	1.20%
Growth in Pre-R&D EBIDTA		27.66%	-8.18%
Growth in EBIDTA		33.41%	-10.92%
Growth in PAT		40.27%	-14.57%
R&D to sales		10.41%	9.85%
Increase in R&D Costs		13.27%	2.06%







MAJOR PROFITABILITY RATIOS

	Q3 Dec 18	9 months- Dec 18
Pre-R&D EBITDA to Income	41.10%	42.06%
EBIDTA to Income	30.69%	32.21%
PAT to Income	18.67%	19.01%
Cash Flow to Income	22.83%	22.88%



Q3 to Q2 COMPARISON


Current quarter to previous quarter





REVENUE COMPARISON

Year on year




5-Feb-19

2018-19 Q3 results



PAT COMPARISON

Year on year




5-Feb-19

2018-19 Q3 results



EBIDTA COMPARISON

Year on year




5-Feb-19

2018-19 Q3 results



R & D – EXPENDITURE

Year on year




5-Feb-19

2018-19 Q3 results



PRE-R&D EBIDTA

Year on year




5-Feb-19

2018-19 Q3 results



PRE-R&D CASHFLOW

Year on year



5-Feb-19

2018-19 Q3 results



FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2018-19 Q3	2018-19 Q2	Growth %	2017-18 Q3	Growth %	2018-19 9 mons	2017-18 9 mons	Growth %
Income	1,347.83	961.08	40.24%	1,669.47	-19.27%	4,306.81	4,255.80	1.20%
Pre-R&D EBITDA	553.90	433.88	27.66%	685.59	-19.21%	1,811.26	1,972.70	-8.18%
Pre-R&D EBITDA Margin	41.10%	45.15%		41.07%		42.06%	46.35%	
EBITDA	413.59	310.01	33.41%	546.81	-24.36%	1,387.19	1,557.19	-10.92%
EBITDA Margin	30.69%	32.26%		32.75%		32.21%	36.59%	
EBIT	356.81	253.71	40.64%	492.40	-27.54%	1,218.34	1,396.97	-12.79%
EBIT Margin	26.47%	26.40%		29.49%		28.29%	32.83%	
Financing costs	5.29	5.91		11.52		21.88	33.58	
Taxes	99.87	68.40		135.15		377.68	404.96	
Net Profit after tax	251.65	179.41	40.27%	345.74	-27.22%	818.78	958.43	-14.57%
NP Margin	18.67%	18.67%		20.71%		19.01%	22.52%	
EPS (basic & diluted not annualised)	1.98	1.41		2.72		6.45	7.54	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	
Depreciation	56.09	55.61		54.17		166.78	159.49	
R&D expenses	140.31	123.87	13.27%	138.78	1.10%	424.07	415.52	2.06%

5-Feb-19

2018-19 Q3 results

News Release



- During the period Suven secures 4 product patents covering Brasil, Eurasia, Australia and Singapore
- Suven presented in B&K Investor Conference - Emergent India in December 2018
- The Board has proposed an Interim Dividend of Re. 1.50 per share (150% of face value of Rs. 1.00 each)



News Release

- Suven Board approved of demerger of Contract Research and Manufacturing Services (CRAMS) undertaking of Suven Life Sciences Limited (SLSL) into Suven Pharmaceuticals Limited (SPL), through a scheme of arrangement, subject to approval of respective regulatory authorities. More details will be notified separately